Earnings Ahead

CHRS - Coherus BioSciences, Inc.

3.84 0.03 0.79

Coherus BioSciences, Inc.

Coherus BioSciences, Inc.

About

Profile

Coherus BioSciences, Inc. is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that may expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug A


Headquarters

Redwood City, California, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

CHRS



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Coherus BioSciences Non-GAAP EPS of -$0.27 misses by $0.03, revenue of $74.6M misses by $7.23M
  • Coherus BioSciences Q3 2023 Earnings Preview
  • Biggest stock movers today: Western Digital, Spirit Realty Capital, On Semiconductor and more
  • Junshi-Coherus' Loqtorzi cancer drug wins FDA approval
  • Coherus updated version of Udenyca rejected by FDA due to inspection
  • Airbnb, Blackstone rise on joining S&P 500 index
  • Coherus BioSciences GAAP EPS of -$0.49 beats by $0.16, revenue of $58.7M beats by $8.22M
  • Coherus BioSciences Q2 2023 Earnings Preview
  • Celltrion launches biosimilar of AbbVie's Humira in US
  • More AbbVie Humira biosimilars launched (updated)
  • Coherus BioSciences acquiring Surface Oncology in up to $65M deal
  • AbbVie, Coherus in legal battle over Humira biosimilar
  • Coherus reports survival data from toripalimab Phase 3 study
  • ASCO 2023: What to look for at oncology's biggest meeting
  • Mark Cuban online pharmacy to offer AbbVie Humira biosimilar
  • Coherus BioSciences falls after regulatory update on cancer drug
  • Junshi's toripalimab gets Chinese regulator review for expanded use in breast cancer
  • Coherus BioSciences down 11%, prices $50M offering
  • Coherus BioSciences plans for $50M stock offering, shares fall
  • Coherus BioSciences Non-GAAP EPS of -$0.75 misses by $0.28, revenue of $32.44M misses by $13.85M
PEERS
/XLV

XLV

Earnings History

Date EPS / Forecast Revenue / Forecast
February 17, 2022 -0.6 / -0.46 73.37M / 82.61M
November 8, 2021 -0.49 / -0.346 82.5M / 90.69M
August 5, 2021 -0.4 / -0.21 87.64M / 87.04M Beat!
May 6, 2021 -2.37 / -0.2067 83.03M / 96.2M
February 24, 2021 0.12 / 0.2149 110.42M / 114.89M
November 5, 2020 0.33 / 0.3544 113.55M / 124.01M
August 6, 2020 0.7 / 0.28 135.67M / 102.52M Beat!
May 7, 2020 0.48 / 0.52 116.18M / 119.44M
February 27, 2020 0.53 / 0.7 123.86M / 125.09M
November 6, 2019 0.63 / 0.48 111.68M / 100.72M Beat!
August 1, 2019 0.32 / -0.04 83.43M / 64.63M Beat!
May 9, 2019 -0.29 / -0.47 37.1M / 36.96M Beat!
February 28, 2019 -0.92 / -0.86 37.10M / 2M Beat!
November 8, 2018 -0.87 / -0.77 37.10M / - Beat!
Date Price Open High Low Vol Change ER
Oct 9, 2023 3.63 3.67
3.73
3.54
2.0M -3.2%
Oct 6, 2023 3.75 3.41
3.8
3.37
3.0M 8.07%
Oct 5, 2023 3.47 3.25
3.48
3.14
3.4M 9.46%
Oct 4, 2023 3.17 3.39
3.41
3.15
2.6M -5.37%
Oct 3, 2023 3.35 3.6
3.6
3.33
2.5M -6.94%
 
Oct 2, 2023 3.6 3.8
3.8
3.59
3.3M -3.74%
Sep 29, 2023 3.74 3.89
3.93
3.72
2.5M -3.36%
Sep 28, 2023 3.87 4
4.01
3.83
1.9M -2.52%
Sep 27, 2023 3.97 4.01
4.09
3.88
1.9M -0.25%
Sep 26, 2023 3.98 4
4.14
3.93
2.4M -1.73%
Sep 25, 2023 4.05 4.36
4.36
4.03
2.8M -9.19%
Sep 22, 2023 4.46 4.15
4.47
4.14
2.7M 7.73%
Sep 21, 2023 4.14 4.45
4.47
4.12
3.7M -8.2%
Sep 20, 2023 4.51 4.56
4.73
4.51
1.7M -2.17%
Sep 19, 2023 4.61 4.53
4.62
4.38
2.4M 1.77%
Sep 18, 2023 4.53 4.86
4.91
4.37
4.0M -7.93%
Sep 15, 2023 4.92 4.79
4.97
4.71
21.1M 2.93%
Sep 14, 2023 4.78 4.71
4.88
4.61
2.1M 2.14%
Sep 13, 2023 4.68 4.96
5.02
4.6
3.5M -7.14%
Sep 12, 2023 5.04 5.01
5.18
5
4.2M -0.2%
Sep 11, 2023 5.05 4.98
5.22
4.96
3.2M 3.27%
Sep 8, 2023 4.89 4.95
5.08
4.76
2.8M 0%
Sep 7, 2023 4.89 4.88
4.94
4.7
2.1M -1.81%
Sep 6, 2023 4.98 4.87
5.07
4.76
2.5M 1.84%
Sep 5, 2023 4.89 5.31
5.33
4.71
7.2M -10.28%
Sep 1, 2023 5.45 5.36
5.47
5.21
2.3M 2.25%
Aug 31, 2023 5.33 5.24
5.4
5.22
1.5M 1.72%
Aug 30, 2023 5.24 5.25
5.35
5.18
1.1M -0.57%
Aug 29, 2023 5.27 5.05
5.28
5.03
2.0M 4.36%
Aug 28, 2023 5.05 4.72
5.07
4.71
1.7M 7.45%
Aug 25, 2023 4.7 4.57
4.72
4.51
1.1M 2.84%
Aug 24, 2023 4.57 4.63
4.63
4.49
946K -1.51%
Aug 23, 2023 4.64 4.72
4.97
4.63
2.1M 0%
Aug 22, 2023 4.64 4.6
4.67
4.43
1.1M 0.87%
Aug 21, 2023 4.6 4.47
4.64
4.36
2.0M 2.91%
Aug 18, 2023 4.47 4.26
4.52
4.22
1.5M 2.76%
Aug 17, 2023 4.35 4.57
4.58
4.34
1.6M -3.97%
Aug 16, 2023 4.53 4.47
4.59
4.43
1.4M 1.34%
Aug 15, 2023 4.47 4.5
4.59
4.41
1.5M -1.32%
Aug 14, 2023 4.53 4.67
4.68
4.42
2.3M -3.21%
Aug 11, 2023 4.68 4.68
4.8
4.67
866K -1.47%
Aug 10, 2023 4.75 4.61
4.88
4.59
1.3M 3.49%
Aug 9, 2023 4.59 4.85
4.88
4.56
1.7M -4.18%
Aug 8, 2023 4.79 5.02
5.02
4.68
2.2M -4.58%
Aug 7, 2023 5.02 5.05
5.11
4.82
2.8M -0.99%
Aug 4, 2023 5.07 5.15
5.22
4.93
2.9M -0.78%
Aug 3, 2023 5.11 4.75
5.25
4.56
7.5M 17.74%
Aug 2, 2023 4.34 4.42
4.57
4.25
4.7M -3.34%
Aug 1, 2023 4.49 4.84
4.84
4.44
3.5M -6.85%
Jul 31, 2023 4.82 4.91
4.93
4.6
2.9M 0.63%
Jul 28, 2023 4.79 4.64
4.83
4.6
2.6M 4.13%
Jul 27, 2023 4.6 4.6
4.73
4.53
2.6M 1.55%
Jul 26, 2023 4.53 4.44
4.54
4.31
1.4M 2.49%
Jul 25, 2023 4.42 4.4
4.65
4.35
1.8M 0.45%
Jul 24, 2023 4.4 4.51
4.74
4.39
2.5M 2.56%
Jul 21, 2023 4.29 4.19
4.4
4.12
1.5M 2.88%
Jul 20, 2023 4.17 4.39
4.53
4.16
1.4M -4.79%
Jul 19, 2023 4.38 4.42
4.5
4.26
2.1M -0.23%
Jul 18, 2023 4.39 4.44
4.68
4.36
1.6M 0.46%
Jul 17, 2023 4.37 4.1
4.6
4.07
3.2M 0%